Challenges of Guarantee-Time Bias

被引:382
作者
Giobbie-Hurder, Anita [1 ]
Gelber, Richard D. [1 ,2 ,3 ]
Regan, Meredith M. [1 ,2 ]
机构
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
关键词
BREAST-CANCER; SURVIVAL; THERAPY; AMENORRHEA; OUTCOMES; MODELS; IMPACT; LONGER; EVENT;
D O I
10.1200/JCO.2013.49.5283
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The potential for guarantee-time bias (GTB), also known as immortal time bias, exists whenever an analysis that is timed from enrollment or random assignment, such as disease-free or overall survival, is compared across groups defined by a classifying event occurring sometime during follow-up. The types of events associated with GTB are varied and may include the occurrence of objective disease response, onset of toxicity, or seroconversion. However, comparative analyses using these types of events as predictors are different from analyses using baseline characteristics that are specified completely before the occurrence of any outcome event. Recognizing the potential for GTB is not always straightforward, and it can be challenging to know when GTB is influencing the results of an analysis. This article defines GTB, provides examples of GTB from several published articles, and discusses three analytic techniques that can be used to remove the bias: conditional landmark analysis, extended Cox model, and inverse probability weighting. The strengths and limitations of each technique are presented. As an example, we explore the effect of bisphosphonate use on disease-free survival (DFS) using data from the BIG (Breast International Group) 1-98 randomized clinical trial. An analysis using a naive approach showed substantial benefit for patients who received bisphosphonate therapy. In contrast, analyses using the three methods known to remove GTB showed no statistical evidence of a reduction in risk of a DFS event with bisphosphonate therapy. (C) 2013 by American Society of Clinical Oncology
引用
收藏
页码:2963 / +
页数:8
相关论文
共 26 条
[1]   Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables [J].
Anderson, James R. ;
Cain, Kevin C. ;
Gelber, Richard D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) :3913-3915
[2]   ANALYSIS OF SURVIVAL BY TUMOR RESPONSE [J].
ANDERSON, JR ;
CAIN, KC ;
GELBER, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) :710-719
[3]   Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodies-EORTC 18991 [J].
Bouwhuis, Marna G. ;
Suciu, Stefan ;
Testori, Alessandro ;
Kruit, Wim H. ;
Sales, Francois ;
Patel, Poulam ;
Punt, Cornelis J. ;
Santinami, Mario ;
Spatz, Alain ;
ten Hagen, Timo L. M. ;
Eggermont, Alexander M. M. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (14) :2460-2466
[4]   Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93 [J].
Colleoni, M ;
Gelber, S ;
Goldhirsch, A ;
Aebi, S ;
Castiglione-Gertsch, M ;
Price, KN ;
Coates, AS ;
Gelber, RD .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) :1332-1341
[5]   Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases [J].
Curtis, Lesley H. ;
Hammill, Bradley G. ;
Eisenstein, Eric L. ;
Kramer, Judith M. ;
Anstrom, Kevin J. .
MEDICAL CARE, 2007, 45 (10) :S103-S107
[6]   Landmark Analysis at the 25-Year Landmark Point [J].
Dafni, Urania .
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2011, 4 (03) :363-U216
[7]  
GAIL MH, 1972, ANN INTERN MED, V76, P815, DOI 10.7326/0003-4819-76-5-815
[8]   Marginal structural models to estimate the joint causal effect of nonrandomized treatments [J].
Hernán, MA ;
Brumback, B ;
Robins, JM .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2001, 96 (454) :440-448
[9]   A GENERALIZATION OF SAMPLING WITHOUT REPLACEMENT FROM A FINITE UNIVERSE [J].
HORVITZ, DG ;
THOMPSON, DJ .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1952, 47 (260) :663-685
[10]   Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study [J].
Montomoli, Jonathan ;
Hamilton-Dutoit, Stephen Jacques ;
Froslev, Trine ;
Taylor, Aliki ;
Erichsen, Rune .
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2012, 5 :167-171